Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma

Thorax

Volumn 67, Issue 2, 2012, Pages 157-163

  Tiev, Kiet Phong ^a   Hua Huy, Thong ^b   Kettaneh, Adrien ^a   Allanore, Yannick ^b   Le Dong, Nhat Nam ^b   Duong Quy, Sy ^b   Cabane, Jean ^a   Dinh Xuan, Anh Tuan ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ACCURACY; ADULT; ALVEOLAR CONCENTRATION OF NITRIC OXIDE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONDUCTING AIRWAYS OUTPUT OF NITRIC OXIDE; DEATH; DETERIORATION; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; FRACTIONED EXHALED NITRIC OXIDE; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY FAILURE; RESPIRATORY TRACT PARAMETERS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; TOTAL LUNG CAPACITY;

EID: 84856060895     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200499     Document Type: Article

References (31)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9. (Pubitemid 24320744)
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
4. Assassi S, Sharif R, Lasky RE, et al GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
5. Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology 2008;47:v48-50.
6. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144:706-13.
7. Tashkin DP, Elashoff R, Clements PJ, et al Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
8. Tashkin DP, Elashoff R, Clements PJ, et al Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34. (Pubitemid 350127847)
9. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Ann Rev Med 2004;55:395-417. (Pubitemid 38316734)
10. Ricciardolo FL, Sterk PJ, Gaston B, et al. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004;84:731-65. (Pubitemid 38823765)
11. Fajac I, Kahan A, Menkes CJ, et al. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998;16:547-52. (Pubitemid 28439436)
12. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998;85:653-66. (Pubitemid 28365835)
13. Girgis RE, Gugnani MK, Abrams J, et al. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002;165:1587-91. (Pubitemid 34693936)
14. Tiev KP, Cabane J, Aubourg F, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007;30:26-30. (Pubitemid 47074002)
15. Hua-Huy T, Tiev KP, Chereau C, et al. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. J Rheumatol 2010;37:1680-7.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
17. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
18. Miller MR, Hankinson J, Brusasco V, et al ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
19. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
20. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
21. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
22. George SC, Hogman M, Permutt S, et al. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004;96:831-9. (Pubitemid 38248651)
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
24. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54. (Pubitemid 351860934)
25. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6. (Pubitemid 34693935)
26. Paredi P, Kharitonov SA, Loukides S, et al. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999;115:1352-6. (Pubitemid 29230646)
27. Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001;119:1449-54. (Pubitemid 32686028)
28. Tiev KP, Le-Dong NN, Duong-Quy S, et al. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide 2009;20:200-6.
29. Tiev KP, Coste J, Ziani M, et al. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:32-8.
30. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
31. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med 2001;163:1557-61. (Pubitemid 32578755)